Zacks Investment Research downgraded shares of Straumann (OTCMKTS:SAUHF) from a strong-buy rating to a hold rating in a report released on Wednesday morning.
According to Zacks, “The Straumann Group is a global leader in implant and restorative dentistry and oral tissue regeneration. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately on thousand seven hundred ninety people worldwide and its products and services are available in more than sixty countries through its broad network of distribution subsidiaries and partners. “
Shares of Straumann (SAUHF) opened at $699.00 on Wednesday. Straumann has a 12 month low of $395.66 and a 12 month high of $753.10. The company has a quick ratio of 2.23, a current ratio of 2.97 and a debt-to-equity ratio of 0.31.
TRADEMARK VIOLATION WARNING: “Straumann (SAUHF) Downgraded by Zacks Investment Research to Hold” was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2017/12/28/straumann-sauhf-downgraded-by-zacks-investment-research-to-hold.html.
Straumann Holding AG provides tooth replacement solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, biomaterials, and digital solutions for use in tooth replacement and restoration or to prevent tooth loss. The company offers replacement solutions, including soft tissue level and bone level implants; SLActive surface for bone formation; Roxolid for use in dental implantology; and ceramic implants.
Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.